Market Overview

UPDATE: Bank of America Upgrades Centene to Buy on Health Care Reform Tailwinds

Share:
Related CNC
Benzinga's Top Downgrades
Barclays Downgrades Centene To Equal-weight
3 Stocks to Buy in the Merger-intense Health Insurance Space - Analyst Blog (Zacks)

Bank of America raised its rating on Centene (NYSE: CNC) from Underperform to Buy and raised its price objective from $39 to $46.

Bank of America commented, "We are upgrading CNC shares to Buy (from Underperform) with a view that companies with Medicaid exposure should benefit from coverage expansions outlined in health care reform legislation. Specifically, the market is likely to refocus on revenue growth driven by states transitioning existing beneficiaries to HMOs (from unmanaged fee for service), dual eligible demonstrations and program enrollment that could increase 20% starting in 2014 as projected by the CBO. We are raising our P.O. to $46 (from $39) on P/E multiple expansion."

Centene Corporation closed at $39.87 on Tuesday.

Latest Ratings for CNC

DateFirmActionFromTo
Jul 2015BarclaysDowngradesOverweightEqual-weight
Jun 2015OppenheimerMaintainsOutperform
Jun 2015BarclaysMaintainsOverweight

View More Analyst Ratings for CNC
View the Latest Analyst Ratings

Posted-In: Bank of AmericaAnalyst Color Upgrades Pre-Market Outlook Analyst Ratings

 

Related Articles (CNC)

Around the Web, We're Loving...

Get Benzinga's Newsletters